Pharma Antes Up: Investment and Business Trends Driving Biotechnology

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Lead Development Deals
  • Pharma-Biotech
  • Biotech-Biotech
• Lead Optimization Deals
• Lead Identifi cation Deals
  • Pharma-Biotech
  • Biotech-Biotech
• Target Identifi cation and Validation Deals
• Mergers and Acquisitions
  • Pharma-Biotech
  • Biotech-Biotech
  • Reverse Mergers
• Outlook: 2007 and Beyond

Tables:

• 1. Select Pharma-Biotech Lead Development Deals with Values More Than $200 Million
• 2. Select Biotech-Biotech Lead Development Deals with Values More than $100 Million
• 3. Select Lead Optimization Deals
• 4. Select Lead Identifi cation Deals
• 5. Select Target Identifi cation and Target Validation Deals
• 6. Select Mergers and Acquisitions

Figures:

• 1. All Life Science Mergers and Acquisitions
• 2. Number of Pharma-Biotech and Biotech-Biotech Mergers and Acquisitions Valued at More Than $100 Million, 2002-2006
• 3. Total Value of Pharma-Biotech and Biotech-Biotech Mergers and Acquisitions Valued at More Than $100 Million, 2002-2006
• 4. Cyclical Nature of the Value of Platform Technologies